



# Brand Drugs Going Generic 2025

Generic drugs are a cost-effective alternative to brand-name medications. They offer the same active ingredients and therapeutic benefits, ensuring safety and efficacy. Approved by the FDA, generic drugs are manufactured to rigorous standards, making them reliable choices for your healthcare needs.

The brand name medications listed below will have generic alternatives becoming available in 2025.

| Brand Name | Generic Name                                    | Treatment  | Expected Availability* |
|------------|---|--|------------------------|
| BEPREVE    | Bepotastine Besilate                            | Itching of the Eyes due to Allergies   | January                |
| SANCUSO    | Granisetron                                     | Nausea and Vomiting caused by Cancer Chemotherapy                                | January                |
| TRILIPIX   | Fenofibrate                                     | Abnormal Blood Lipid Levels  | January                |
| VYZULTA    | Latanoprostene Bunod                            | Intraocular Pressure in Patients with Open-angle Glaucoma or Ocular Hypertension | January and October    |
| ARCAPTA    | Indacaterol                                     | Chronic Obstructive Pulmonary Disease (COPD)                                     | February               |
| BOSULIF    | Bosutinib Monohydrate                           | Chronic Myeloid Leukemia (CML) Acuet Lymphoblastic Leukemia                      | February               |
| DUAKLIR    | Aclidinium bromide/formoterol                   | Chronic Obstructive Pulmonary Disease (COPD)                                     | February               |
| RUKOBIA    | Fostemsavir                                     | HIV/AIDS   | February               |
| VIBERZI    | Eluxadoline                                     | Diarrhea and Abdominal Pain  | March                  |
| YUPELRI    | Revefenacin                                     | Chronic Obstructive Pulmonary Disease (COPD)                                     | March                  |
| ANTARA     | Fenofibrate                                     | High Cholesterol and Triglycerides (fatty acids) in Blood                        | April                  |
| BIKTARVY   | Bictegravir/emtricitabine/tenofovir alafenamide | HIV/AIDS   | April                  |
| INLYTA     | Axitinib  | Renal Cell Carcinoma   | April                  |
| LYSTEDA    | Tranexamic Acid                                 | High cholesterol and triglycerides (fatty acids) in blood                        | April                  |
| EDARBI     | Azilsartan                                      | Hypertension   | May                    |
| JENTADUETO | Linagliptin/metformin hydrochloride             | High Blood Sugar Levels-Type 2 Diabetes  | May                    |
| KAZANO     | Alogliptin/metformin                            | Blood Sugar Control in Adults with Type 2 Diabetes                               | June                   |
| NUCYNTA    | Tapentadol hydrochloride                        | Moderate to Severe Pain  | June                   |
| DUZALLO    | Lesinurad/Allopurinol                           | Gout   | August                 |
| NUPLAZID   | Pimavanserin                                    | Parkinson's disease psychosis  | September              |
| PROLENSEA  | Bromfenac                                       | Ocular Inflammation and Pain after Cataract Surgery                              | September              |
| CRESEMBA   | Isavuconazonium Sulfate                         | Invasive Aspergillosis And mucormycosis  | October                |
| LATUDA     | Lurasidone                                      | Thyroid Cancer   | October                |
| NEXLIZET   | Bempedoic Acid, Ezetimibe                       | Reduce the Amount of Cholesterol and other Fatty Substances in Blood             | December               |
| SPRYCEL    | Dasatinib                                       | Chronic Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia      | December               |

\*These are the current expected available dates and are subject to change